Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT01068756 · ClinicalTrials.gov registry record · Phase 1
Effect of Rifampin on the Pharmacokinetics of Dapagliflozin in Healthy Subjects
A Phase 1 study, sponsored by AstraZeneca.
- Terminated
- Registry status
- Phase 1
- Development phase
- 14
- Enrollment target
NCT01068756: Clinical Trial Phase 1 study, sponsored by AstraZeneca.
NCT01068756 is a Phase 1 study that was terminated before completion, run by AstraZeneca. The registered enrollment target is 14 participants, below the 60-participant average among 29,502 other Phase 1 trials with a reported enrollment target (77% lower). According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT01068756, a Phase 1 study, was terminated before completion, sponsored by AstraZeneca.
- TERMINATED
- Registry status
- Phase 1
- Development phase
- 14 participants
- Enrollment target
Study Summary
The purpose of the study is to assess the effects of rifampin on the pharmacokinetics of dapagliflozin
Interventions
- DRUG Rifampin
- DRUG Dapagliflozin
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 14 participants |
| Start Date | 2010-03 |
| Est. Completion | 2010-04 |
| Phase | Phase 1 |
Why NCT01068756 stopped before completion
NCT01068756 is an interventional study that assigns participants to a tested intervention. The registry caps enrollment at 14 participants, a relatively small participant target, below the 60-participant average among 29,502 other Phase 1 trials with a reported enrollment target (77% lower).
The record links to 0 conditions, and to 2 interventions - of which Rifampin is the first listed.
NCT01068756 does not publish any study locations in the registry export this page uses.
Frequently Asked Questions
What is clinical trial NCT01068756 about?
NCT01068756 is a clinical study titled "Effect of Rifampin on the Pharmacokinetics of Dapagliflozin in Healthy Subjects". The purpose of the study is to assess the effects of rifampin on the pharmacokinetics of dapagliflozin
What is the current status of trial NCT01068756?
This trial is currently terminated. It is a Phase 1 study. The enrollment target is 14 participants. The study started on 2010-03. Estimated completion is 2010-04.
What interventions are being tested in trial NCT01068756?
The interventions under investigation include: Rifampin (DRUG), Dapagliflozin (DRUG).
Who is sponsoring clinical trial NCT01068756?
This trial is sponsored by AstraZeneca, which has 1,285 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
How this trial's enrollment target compares
Where NCT01068756's enrollment target sits among peer trials
14 1844th of 2000 higher than 154 of 2,000 other Phase 1 trials
participants (enrollment target), bucketed by value
Each bar is a band; taller bars hold more other Phase 1 trials. The dashed line + filled bar mark this entry. Hover or tap any bar for its full count and share, and where it sits relative to this entry.
Source ClinicalTrials.gov registry export · 2026-08-08
Nationwide trials with similar profiles
Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.
Similar enrollment target
- NCT02523092 · 14 participants · Phase 4
Use of CXCL9 as a Biomarker of Acthar Efficacy
- NCT04263285 · 14 participants · NA
Treatment of Depression Post-SCI
- NCT04743271 · 14 participants · NA
Food and Circadian Timing
- NCT05065671 · 14 participants · Phase 1
Microbiome Derived Metabolism and Pharmacokinetics
Similar registry start date
- NCT05988463 · started 2027-01-01 · Phase 1
Dose-Escalation Study of Artesunate Patients With IPF
- NCT07219706 · started 2026-12-10 · NA
Dietary Fiber and Time Restricted Eating
- NCT02831335 · started 2026-12-01
Technical Development of Multi-Parametric Renocerebral MRI
- NCT05962346 · started 2026-12 · NA
Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia